Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Vacunación frente a tuberculosis

  • Martin, Carlos
  • Aguilo, Nacho
  • Gonzalo-Asensio, Jesús
La vacunación con BCG (bacilo Calmette-Guérin) está incluida en el calendario de inmunización al nacimiento en países con alta incidencia de tuberculosis, con una cobertura global cercana al 90%. BCG tiene casi cien años de antigüedad y está basada en una cepa atenuada de Mycobacterium bovis, proporcionando protección contra las formas diseminadas de la enfermedad pero confiriendo una protección muy limitada contra las formas pulmonares de tuberculosis, responsables de su transmisión. Diferentes vacunas profilácticas contra la tuberculosis se encuentran hoy en desarrollo clínico para reemplazar a BCG o para mejorar la protección en individuos ya vacunados con BCG. MTBVAC es la primera y única vacuna candidata basada en una cepa de Mycobacterium tuberculosis atenuada en evaluación clínica. Los planes de desarrollo clínico del MTBVAC se dirigen en primer lugar a la prevención de la tuberculosis en recién nacidos, para reemplazar a BCG, y en segundo lugar en adolescentes y adultos.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Reseña (Review)

Update on TB vaccine pipeline

  • Martin, Carlos
  • Aguilo, Nacho
  • Marinova, Dessislava
  • Gonzalo-Asensio, Jesús
In addition to antibiotics, vaccination is considered among the most efficacious methods in the control and the potential eradication of infectious diseases. New safe and effective vaccines against tuberculosis (TB) could be a very important tool and are called to play a significant role in the fight against TB resistant to antimicrobials. Despite the extended use of the current TB vaccine Bacillus Calmette-Guerin (BCG), TB continues to be transmitted actively and continues to be one of the 10 most important causes of death in the world. In the last 20 years, different TB vaccines have entered clinical trials. In this paper, we review the current use of BCG and the diversity of vaccines in clinical trials and their possible indications. New TB vaccines capable of protecting against respiratory forms of the disease caused by sensitive or resistant Mycobacterium tuberculosis strains would be extremely useful tools helping to prevent the emergence of multi-drug resistance.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

BCG vaccination improves DTaP immune responses in mice and is associated with lower pertussis incidence in ecological epidemiological studies

  • Broset, E.
  • Pardo-Seco, J.
  • Kanno, A.I.
  • Aguilo, N.
  • Dacosta, A.I.
  • Rivero-Calle, I.
  • Gonzalo-Asensio, J.
  • Locht, C.
  • Leite, L.C.C.
  • Martin, C.
  • Martinón-Torres, F.
Background: The Bacillus Calmette-Guérin (BCG), the only vaccine against tuberculosis (TB) currently in use, has shown beneficial effects against unrelated infections and to enhance immune responses to vaccines. However, there is little evidence regarding the influence of BCG vaccination on pertussis. Methods: Here, we studied the ability of BCG to improve the immune responses to diphtheria, tetanus, and acellular (DTaP) or whole-cell pertussis (DTwP) vaccination in a mouse model. We included MTBVAC, an experimental live-attenuated vaccine derived from Mycobacterium tuberculosis, in our studies to explore if it presents similar heterologous immunity as BCG. Furthermore, we explored the potential effect of routine BCG vaccination on pertussis incidence worldwide. Findings: We found that both BCG and MTBVAC when administered before DTaP, triggered Th1 immune responses against diphtheria, tetanus, and pertussis in mice. Immunization with DTaP alone failed to trigger a Th1 response, as measured by the production of IFN-¿. Humoral responses against DTaP antigens were also enhanced by previous immunization with BCG or MTBVAC. Furthermore, exploration of human epidemiological data showed that pertussis incidence was 10-fold lower in countries that use DTaP and BCG compared to countries that use only DTaP. Interpretation: BCG vaccination may have a beneficial impact on the protection against pertussis conferred by DTaP. Further randomized controlled trials are needed to properly define the impact of BCG on pertussis incidence in a controlled setting. This could be a major finding that would support changes in immunization policies.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Safety, reactogenicity, and immunogenicity of MTBVAC in infants: a phase 2a randomised, double-blind, dose-defining trial in a TB endemic setting

  • Tameris, Michele
  • Rozot, Virginie
  • Imbratta, Claire
  • Geldenhuys, Hennie
  • Mendelsohn, Simon C.
  • Kany Luabeya, Angelique Kany
  • Shenje, Justin
  • Tredoux, Nicolette
  • Fisher, Michelle
  • Mulenga, Humphrey
  • Bilek, Nicole
  • Young, Carly
  • Veldsman, Ashley
  • Botes, Natasja
  • Thole, Jelle
  • Fritzell, Bernard
  • Mukherjee, Rajat
  • Jelsbak, Ingrid Murillo
  • Rodriguez, Esteban
  • Puentes, Eugenia
  • Doce, Juana
  • Marinova, Dessislava
  • Gonzalo-Asensio, Jesús
  • Aguilo, Nacho
  • Martin, Carlos
  • Scriba, Thomas J.
  • Hatherill, Mark
  • Abrahams, Charmaine
  • Africa, Hadn
  • Arendsen, Denis
  • Barnard, Liezl
  • Cloete, Yolundi
  • Davids, Ilse
  • Erasmus, Mzwandile
  • Filander, Elizabeth
  • Gregg, Yolande
  • Herling, Roxane
  • Jansen, Ruwiyda
  • Jack, Lungisa
  • Kelepu, Xoliswe
  • Kyepa, Henriette
  • Leopeng, Thelma
  • Mabwe, Simbarahse
  • Mactavie, Lauren
  • Makhete, Lebohang
  • Mangali, Sandisiwe
  • Mouton, Angelique
  • Nkambule, Hlengiwe
  • Noble, Julia
  • Nombida, Onke
  • Nqakala, Nambitha
  • Opperman, Fajwa
  • Raphela, Rodney
  • Rossouw, Susan
  • Schoeman, Elisma
  • Schreuder, Constance
  • Steyn, Marcia
  • Swanepoel, Liticia
  • Toefy, Asma
  • Tromp, Anele
  • Tyambethu, Petrus
  • Valley, Habibullah
  • Van Rooyes, Johanna
Safer and more effective tuberculosis (TB) vaccines than Bacille Calmette Guérin (BCG) are needed. We evaluated the safety, reactogenicity, and immunogenicity of three dose levels of the live-attenuated Mycobacterium tuberculosis (Mtb) vaccine, MTBVAC, compared to BCG, in South African infants. Methods. Healthy, HIV-unexposed, BCG-naïve infants were randomised to receive a single intradermal dose of BCG (2.5 × 105 CFU, n = 24) or MTBVAC (2.5 × 104, 2.5 × 105, or 2.5 × 106 CFU, each n = 25). Safety endpoints were solicited systemic, solicited injection site, and unsolicited adverse events (AE), and serious AE (SAE). Immunogenicity was measured using interferon-γ release assay (IGRA) and whole blood intracellular cytokine staining assay. Follow-up was 12 months post-vaccination. Findings. Ninety-nine infants were enrolled between 18 February 2019 and 08 March 2021. Seventy-eight infants experienced reactogenicity AE (all mild except one grade 2 erythema). Induration, swelling, and erythema were more frequent as MTBVAC dose increased. All reactogenicity events were less frequent in infants receiving MTBVAC 2.5 × 105 CFU compared with BCG. Twelve infants (three BCG and nine MTBVAC recipients) experienced 14 vaccine-unrelated SAE, including one death due to bronchopneumonia (MTBVAC recipient). Eight infants were treated for unconfirmed pulmonary TB (four BCG and four MTBVAC 2.5 × 104 CFU recipients); one BCG recipient was treated for unconfirmed TB meningitis. MTBVAC was immunogenic at all 3 doses, inducing predominantly Th1-cytokine-expressing CD4 T cells, which peaked at Day 56. The 2.5 × 105 and 2.5 × 106 CFU MTBVAC doses induced similar response magnitudes and were more immunogenic than BCG. Day 56 IGRA conversion was observed in 61 (87.4%) infants receiving any MTBVAC dose, but only 28 (42.4%) remained positive by Day 365. Interpretation. MTBVAC appeared safe, well-tolerated, and immunogenic at doses between 2.5 × 104 and 2.5 × 106 CFU in South African infants. The 2.5 × 105 CFU MTBVAC dose, being less reactogenic and more immunogenic than BCG, was selected for a multi-centre, phase 3 trial.